The independent medical news service
19-09-2021 | Oncology | News | Article
ARCHES reports enzalutamide OS benefit in men with mCSPC
The final analysis of the ARCHES trial has demonstrated a significant overall survival boost with the addition of enzalutamide instead of placebo to androgen deprivation therapy in the metastatic castration-sensitive prostate cancer setting.
Red heart with stethoscope on blue background/© denissimonov / stock.adobe.com